Intensified, extended therapy for high-risk myeloma held its survival advantage at five years

Design

Multicentre, externally controlled, phase 2 trial with Bayesian design (5-year follow-up)

Population

107 UK patients with newly diagnosed high-risk myeloma or plasma cell leukaemia; 120 matched controls

Primary outcome

Progression-free survival, PFS2 and overall survival at 5 years

Effect

PFS HR 0.32 (0.22–0.45); OS HR 0.43 (0.28–0.65) vs matched Myeloma XI cohort

OPTIMUM, a UK phase 2 trial with an external control, reported five-year results in Lancet Oncology on 7 September. It treated 107 patients with newly diagnosed high-risk multiple myeloma or plasma cell leukaemia with intensified quadruplet induction including daratumumab, transplant, two-part consolidation and daratumumab-lenalidomide maintenance, and compared them with 120 genetically matched patients from the Myeloma XI trial.

Median progression-free and overall survival had not been reached in OPTIMUM, against 24.4 and 57.4 months in the matched controls (HRs 0.32 and 0.43). The benefit held across high-risk subgroups except those with three or more high-risk cytogenetic abnormalities.

The practical lesson is diagnostic as much as therapeutic: identifying high-risk disease at diagnosis, through cytogenetics or gene expression, is what makes tailored intensification possible.

The comparison is with a historical external cohort treated without daratumumab, so part of the difference reflects era and drug availability rather than the strategy alone.

• Obtain cytogenetic risk assessment at myeloma diagnosis to identify high-risk disease.
• Consider intensified induction and extended consolidation for high-risk patients where available.
• Patients with three or more high-risk abnormalities did not share the benefit and need trial options.
• Daratumumab-based quadruplets and maintenance may be limited by cost in India.

Why it matters

It supports treating high-risk myeloma as a distinct disease rather than with the standard pathway.

Don't overread it

This was a single-arm phase 2 trial compared with an older external control, not a randomised comparison.

The statistics, in plain English

An overall survival hazard ratio of 0.43 (95% CI 0.28 to 0.65) against a matched historical group is large, but external controls cannot account for changes in care over time, so the true strategy effect is likely smaller.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.